Pharmaceutical Competition

It should be noted that ethical pharmaceutical products (prescription and trademark defined) suffered a considerable decline despite the constant attempts to be well positioned as the influx of patients to hospitals and clinics is steadily decreasing in significant percentages. The generic (no brand) took the lead because of its low cost and are pharmacies who are more opportunities for the supply. The predominant routes of administration of pharmaceuticals generally are crucial because of its low cost, rapid absorption and the immediate effect of them. Presenting change options to best presentation are sold cheaper than hospital presentations. Medical prescriptions are hampered by self-medication in avoiding large-scale participation of the physician. Pharmaceutical specialties undergo a change also important in relation to the specialty to which they are directed by such general medicine, pediatrics and gynecology, which can be regarded as leading specialties over internal medicine, dermatology, gastroenterology, which are not high medical consultation.

The combined requirements, which include a long list of products is greatly reduced to low-cost commodity for the same patient and at the time of purchase due to their low economic resources can not meet medical requirements. Competition between ethical brand products with similar active substances is steadily increasing by substituting a low-cost generic products to patients. For these reasons, a brief analysis of the pharmaceutical market in underdeveloped countries can deduce that in the coming years the conduct of the physician and patient will be directed to the generic pharmaceutical products, since the economic crisis is notable mainly in countries where the economy is steadily deteriorating.